Search

Search Constraints

You searched for: Author/Creator Illidge, Tim

Search Results

1. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Issue 3 (March 2021)

3. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Issue 3 (March 2015)

4. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. (16th October 2017)

5. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Issue 10168 (19th January 2019)

8. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Issue 1 (9th March 2020)

9. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Issue 11 (November 2013)